Yubo International Biotech Ltd (YBGJ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-250K 0 250K 500K 750K Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q2 '22: 453.8K Q3 '22: 370K Q4 '22: 104.3K Q1 '23: 245.7K Q2 '23: 239.1K Q3 '23: 653.1K Q4 '23: 608.8K Q1 '24: 455.7K Q2 '24: 454.3K Q3 '24: 25.8K Q4 '24: 3.5K Q1 '25: -18 Q2 '25: -18 Q3 '25: -18 Q4 '25: 12.4K Q1 '26: 12.4K Q2 '26: 12.4K Q3 '14 Q1 '16 Q3 '17 Q1 '19 Q3 '20 Q2 '23 Q4 '24 Q2 '26

Gross Profit TTM

-600K 0 600K 1.2M 1.8M Q4 '20: 1.2M Q1 '21: 1.5M Q2 '21: 1.5M Q3 '21: 1.4M Q4 '21: 820.6K Q1 '22: 513.3K Q2 '22: 306.2K Q3 '22: 242.6K Q4 '22: 52.7K Q1 '23: 102.1K Q2 '23: 97.1K Q3 '23: 431.6K Q4 '23: 420.7K Q1 '24: 365.7K Q2 '24: 364.8K Q3 '24: 20.7K Q4 '24: 2.6K Q1 '25: -13 Q2 '25: -13 Q3 '25: -13 Q4 '25: 8.2K Q1 '26: 8.2K Q2 '26: 8.2K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '11: -49K Q4 '11: -49K Q1 '12: -47K Q2 '12: -46K Q3 '12: -49K Q4 '12: -55K Q1 '13: -60K Q2 '13: -60K Q3 '13: -60K Q4 '13: -55K Q1 '14: -55K Q2 '14: -57K Q3 '14: -57K Q4 '14: -60K Q1 '15: -57K Q2 '15: -57K Q3 '15: -64K Q4 '15: -61K Q1 '16: -63K Q2 '16: -64K Q3 '16: -57K Q4 '16: -67K Q1 '17: -150K Q2 '17: -157K Q3 '17: -165K Q4 '17: -163K Q1 '19: -48K Q2 '19: -35K Q3 '19: -31K Q4 '19: -32K Q1 '20: -28K Q3 '21: -1.4M Q4 '21: -1.5M Q1 '22: -1.7M Q2 '22: -1.8M Q3 '22: -1.7M Q4 '22: -1.2M Q1 '23: -942.8K Q2 '23: -818.6K Q3 '23: -573.9K Q4 '23: -1.2M Q1 '24: -1.3M Q2 '24: -1.4M Q3 '24: -1.9M Q4 '24: -1.8M Q1 '25: -1.8M Q2 '25: -1.6M Q3 '25: -1.4M Q4 '25: -1.3M Q1 '26: -1.1M Q2 '26: -1.1M Q4 '11 Q3 '13 Q2 '15 Q1 '17 Q4 '19 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q2 '11: -109K Q3 '11: -83K Q4 '11: -84K Q1 '12: -84K Q2 '12: -84K Q3 '12: -88K Q4 '12: -96K Q1 '13: -103K Q2 '13: -105K Q3 '13: -107K Q4 '13: -104K Q1 '14: -106K Q2 '14: -110K Q3 '14: -113K Q4 '14: -118K Q1 '15: -116K Q2 '15: -118K Q3 '15: -127K Q4 '15: -126K Q1 '16: -130K Q2 '16: -133K Q3 '16: -128K Q4 '16: -140K Q1 '17: -225K Q2 '17: -234K Q3 '17: -244K Q4 '17: -244K Q1 '18: -144K Q2 '18: -146K Q3 '18: -140K Q4 '18: -130K Q1 '19: -148K Q2 '19: -137K Q3 '19: -135K Q4 '19: -136K Q1 '20: -134K Q3 '21: -1.4M Q4 '21: -1.5M Q1 '22: -1.7M Q2 '22: -1.8M Q3 '22: -1.7M Q4 '22: -1.2M Q1 '23: -942.7K Q2 '23: -818.5K Q3 '23: -574.1K Q4 '23: -1.2M Q1 '24: -1.3M Q2 '24: -1.4M Q3 '24: -2M Q4 '24: -1.7M Q1 '25: -1.7M Q2 '25: -1.4M Q3 '25: -1.1M Q4 '25: -1.2M Q1 '26: -990.1K Q2 '26: -1M Q4 '12 Q3 '14 Q2 '16 Q1 '18 Q4 '19 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

-150K 0 150K 300K 450K Q4 '20: 160.8K Q1 '21: 307.5K Q2 '21: 422.7K Q3 '21: 384.9K Q4 '21: 423.7K Q1 '22: 283.9K Q2 '22: 147.6K Q3 '22: 127.5K Q4 '22: 51.6K Q1 '23: 143.6K Q2 '23: 142K Q3 '23: 221.5K Q4 '23: 188.1K Q1 '24: 90K Q2 '24: 89.5K Q3 '24: 5.1K Q4 '24: 822 Q1 '25: -5 Q2 '25: -5 Q3 '25: -5 Q4 '25: 4.2K Q1 '26: 4.2K Q2 '26: 4.2K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '11: -45K Q4 '11: -41K Q1 '12: -43K Q2 '12: -42K Q3 '12: -40K Q4 '12: -42K Q1 '13: -38K Q2 '13: -38K Q3 '13: -48K Q4 '13: -48K Q1 '14: -46K Q2 '14: -69K Q3 '14: -50K Q4 '14: -65K Q1 '15: -63K Q2 '15: -51K Q3 '15: -67K Q4 '15: -53K Q1 '16: -56K Q2 '16: -50K Q3 '16: -43K Q4 '16: -44K Q1 '17: -55K Q2 '17: -69K Q3 '17: -70K Q4 '17: -75K Q1 '18: -55K Q2 '18: -44K Q3 '18: -35K Q4 '18: -23K Q1 '19: -32K Q2 '19: -29K Q3 '19: -27K Q4 '19: -28K Q1 '20: -22K Q4 '21: -1M Q1 '22: 32.7K Q2 '22: -61.2K Q3 '22: 24.9K Q4 '22: -601K Q1 '23: -684.6K Q2 '23: -820K Q3 '23: -870.1K Q4 '23: -739K Q1 '24: -1M Q2 '24: -1.3M Q3 '24: -963.4K Q4 '24: -1.3M Q1 '25: -1.4M Q2 '25: -985.5K Q3 '25: -1.6M Q4 '25: -842.8K Q1 '26: -657.9K Q2 '26: -728K Q3 '12 Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q4 '21: -1.6M Q1 '22: -90.1K Q2 '22: -83.3K Q3 '22: 6.9K Q4 '22: -601K Q1 '23: -694.2K Q2 '23: -820K Q3 '23: -870.1K Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q3 '19: 1.2M Q4 '19: 1.2M Q3 '20: 1.2M Q4 '20: 89.7M Q3 '23: 119.8M Q1 '24: 12M Q2 '24: 119.8M Q3 '24: 119.8M Q1 '25: 119.8M Q2 '25: 119.8M Q3 '25: 147.9M Q1 '26: 170.4M Q2 '26: 170.4M Q3 '19 Q3 '20 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.24 -0.16 -0.08 0.00 0.08 0.16 0.24 Q2 '11: -0.01 Q3 '11: -0.07 Q4 '11: -0.07 Q1 '12: -0.07 Q2 '12: -0.07 Q3 '12: -0.07 Q4 '12: -0.08 Q1 '13: -0.09 Q2 '13: -0.09 Q3 '13: -0.09 Q4 '13: -0.08 Q1 '14: -0.08 Q2 '14: -0.08 Q3 '14: -0.08 Q4 '14: -0.09 Q1 '15: -0.09 Q2 '15: -0.10 Q3 '15: -0.11 Q4 '15: -0.11 Q1 '16: -0.11 Q2 '16: -0.11 Q3 '16: -0.11 Q4 '16: -0.12 Q1 '17: -0.20 Q2 '17: -0.21 Q3 '17: -0.21 Q4 '17: -0.21 Q1 '18: -0.12 Q2 '18: -0.12 Q3 '18: -0.12 Q4 '18: -0.11 Q1 '19: -0.13 Q2 '19: -0.12 Q3 '19: -0.12 Q4 '19: -0.12 Q1 '20: -0.11 Q2 '24: -0.09 Q3 '24: -0.10 Q4 '24: -0.02 Q1 '25: -0.02 Q2 '25: -0.02 Q3 '25: -0.01 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q4 '11 Q2 '13 Q4 '14 Q2 '16 Q4 '17 Q2 '19 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.